Skip to content

G&A at other companies

DaVita logo
DaVitaDVA
$421.91M+12.8%
InfuSystem Holdings logo
InfuSystem HoldingsINFU
$14.8M-3.3%
Teladoc Health logo
Teladoc HealthTDOC
$102.09M-9.5%
ARD
Ardent Health PartnersARDT
$48.6M+39.3%

Other financials

Income statement

See full
Revenue$27.9M-6.3%
Gross profit$12.1M+9.3%
Operating income-$16.9M-3.2%
Net income-$19.0M+26.4%
EPS (diluted)-$1.03+71.9%

Balance sheet

See full
Cash & equivalents$30.6M-59.7%
Total debt$101.6M+3.5%
Total equity$111.7M-34.3%
Total assets$249.5M-17.2%

Cash flow

See full
Operating cash flow-$12.8M+50.0%
CapEx$65.0K-47.2%
Free cash flow-$12.9M+49.9%

Valuation

See full
Market cap$80.08M-75.5%
Enterprise value$151.13M-61.9%
P/S0.7×-2.1×

Profitability

See full
Gross margin40.6%+4.7pp
Operating margin-57.2%-12.9pp
Net margin-63.7%-16.7pp
FCF margin-29.1%-11.5pp

Returns & leverage

See full
Return on equity-53.2%-14.8pp
Debt / equity0.9×+0.3×
Current ratio6.3×-2.1×

Where this comes from

Reported directly by Outset Medical, Inc. in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The official record: Outset Medical, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Outset Medical, Inc.'s g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Outset Medical, Inc.'s G&A?
Outset Medical, Inc. (OM) reported G&A of $10.12M in Q1 2026.
How has Outset Medical, Inc.'s G&A changed year-over-year?
Outset Medical, Inc.'s G&A increased by 21.9% year-over-year, from $8.3M to $10.12M.
What is the long-term trend for Outset Medical, Inc.'s G&A?
Over 4 years (2021 to 2025), Outset Medical, Inc.'s G&A has grown at a 1.0% compound annual growth rate (CAGR), from $36.32M to $37.86M.
What does G&A mean?
Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.